Abstract:Abstract: Objective: To compare the clinical efficacy of spinal cord stimulation(SCS)and gabapentin as the preferred treatment options for zoster-related neuralgia(ZRN),respectively. Methods: A retrospective analysis of 60 patients with herpes zoster neuralgia diagnosed in our hospital from September 2018 to January 2022,they were divided into group A and group B, both underwent antiviral treatment. Group A received short-course SCS after completing admission related examination, and group B underwent standardized gabapentin capsule drug treatment.VAS score, McGill score, sleep quality, the temperature difference between the affected and healthy skin in the skin infrared thermal imaging map ΔT and postherpetic neuralgia (PHN) were recorded at each time point before surgery, 7 days, 14 days, 28 days and 3 months, and statistical analysis of data was conducted. Results:Comparison of VAS score, McGill score, the temperature difference between the affected and healthy skin in the skin infrared thermal imaging map ΔT between the two groups showed no statistically significant difference before surgery; At each postoperative follow-up time point, both groups were significantly lower than preoperative (P<0.05), and group A was significantly lower than group B (P<0.001).The number of affected sleep quality in both groups was decreased at the postoperative follow-up time points (P<0.05), and group A was significantly lower than group B (P<0.001). Moreover, at 3 months, group A decreased compared with 28 days(P<0.05), while group B increased(P<0.05). The incidence of PHN was significantly lower in Group A (6.67%) compared with B (30%) (P<0.05) at 1 month after surgery, at 3 months, group A (3.33%) further lower than before,group B (33.33%) increased from before,moreover, group A was significantly lower compared with group B (P<0.05). Conclusion:Both treatments are effective, but spinal cord stimulation as the preferred treatment regimen can significantly relieve patient pain, improve patient quality of life, and significantly reduce the occurrence of postherpetic neuralgia.